Manufacturing Facilities
VIRxSYS is the only company currently utilizing a lentiviral vector in a Phase II clinical trial approved by the FDA. Consequently, VIRxSYS is uniquely positioned to manufacture clinical-grade lentiviral vectors for therapies treating a wide range of life-threatening diseases.
VIRxSYS both manufactures clinical grade lentiviral vectors and performs cell processing for clinical trials at its Gaithersburg, Maryland facility. Our manufacturing facility includes two class-10,000 clean rooms for vector production and patient cell processing. In addition, the company has a dedicated plasmid production room, a suite of quality control labs, and a variety of support rooms.
In addition to our manufacturing facilities, VIRxSYS has extensive research and development facilities and capabilities dedicated to supporting the Company’s manufacturing and clinical trial initiatives, and to developing a pipeline of therapies for additional disease indications.
"VIRxSYS's lentiviral manufacturing capabilities and cell processing are unmatched anywhere in the world."
Gary McGarrity, VIRxSYS EVP Scientific and Clinical Affairs